Loading company…
Sigilon Therapeutics, Inc. develops cell therapies on a proprietary platform and was acquired by Eli Lilly and Company in 2023.
Sigilon Therapeutics, Inc. develops cell therapies for chronic diseases and genetic disorders, using a proprietary platform that enables sustained delivery of therapeutic proteins. Founded in 2015 in Cambridge, US, by co-founders Daniel Anderson and Omid Veiseh, the company is led by CEO Rogério Vivaldi and is listed at the Series B stage. It completed an IPO in December 2020 that raised USD 126 mn, and Eli Lilly and Company acquired it in June 2023 for USD 309.60 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in